- Investing.com
Perspective Therapeutics, Inc., together with its subsidiaries, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. The company discovers, and develop its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha; and PSV4XX, a differentiated prostate-specific membrane antigen-targeted alpha therapy. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.
Radiopharmaceutical Pionee | Perspective Therapeutics leads in targeted cancer therapies with its innovative lead-specific chelator technology and diverse pipeline, positioning itself as a key player in the RPT space. |
Clinical Progress | Explore the company's advancing VMT-α-NET program, with expanded patient enrollment and promising initial safety profiles, signaling confidence in its therapeutic potential. |
Financial Outlook | Analysts maintain a strong buy consensus with an average price target of $16, balancing short-term caution against long-term optimism for CATX's platform and pipeline. |
Strategic Advantages | Delve into CATX's decentralized manufacturing strategy and robust patent estate, potentially offering improved efficiency and a competitive edge in commercialization. |
Metrics to compare | CATX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCATXPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.4x | −1.9x | −0.5x | |
PEG Ratio | −0.11 | −0.11 | 0.00 | |
Price/Book | 1.0x | 2.1x | 2.6x | |
Price / LTM Sales | 194.8x | 10.3x | 3.3x | |
Upside (Analyst Target) | 285.6% | 277.4% | 43.5% | |
Fair Value Upside | Unlock | 15.5% | 6.3% | Unlock |